Formulary E-news :
Having trouble viewing this e-mail? Click here.
You are subscribed to %%list.name%% as %%emailaddr%%.
Unsubscribe from this list.
Formulary E-news
Modern Medicine Network
 
 
 
 
 
TOP SEARCHES: Certolizumab // Liraglutide // Comparative effectiveness
In this issue
CPOE and safety
Acid-suppressive drugs
Sipuleucel-T, prostate cancer
Pediatric depression
Key Topic Updates

Survey

This month we would like to know...

Have diagnoses of pediatric depression increased at your healthcare organization in recent years?

Vote in our survey, and see what other P&T committee members have to say.
Click here to vote

Contact Us
Click here to contact a Formulary editor.

Click here to contact a Formulary sales representative.

Click here to learn about direct mail, reprints and classifieds in Formulary.

JUNE 16, 2009
Inconsistent communication within CPOE poses significant safety risks
A prospective study published in Archives of Internal Medicine demonstrated that despite standardization of data entry within the computerized provider order entry (CPOE) system in a specific healthcare facility, inconsistent communication in orders entered into the CPOE posed a significant safety risk. More...
Acid-suppressive medications associated with increased risk of hospital-acquired pneumonia
A prospective pharmacoepidemiologic cohort study published in JAMA demonstrated that hospitalized patients treated with acid-suppressive medications were 30% more likely to develop hospital-acquired pneumonia than those who were not treated with acid-suppressive medications. This increased risk was statistically significant for patients treated with proton-pump inhibitors (PPIs) but not for those treated with histamine2-receptor antagonists. More...
Immunotherapy improves survival in advanced prostate cancer
Sipuleucel-T represents the “first active immunotherapy to demonstrate improvement in overall survival for advanced prostate cancer,” said David Penson, MD, MPH, who announced the results of a phase 3 study known as Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT), at the American Urological Association (AUA) 2009 Annual Meeting. More...
Overview of depression and its management in children and adolescents
Recently there has been an increase in the diagnosis of major depressive disorder (MDD) in school-aged children and adolescents. MDD can be triggered by multiple stressors and carries the potential for comorbid conditions in this patient population. This review addresses the prevalence and management of MDD in school-aged children and adolescents, including treatment guidelines and agents under investigation for this indication. More...
 
Key Topic Updates
Medication Safety
Golimumab associated with risk of serious fungal infections
ADA: Rosiglitazone effect on heart attack risk studied
Sedatives, hypnotics linked to suicide risk in elderly
Depression diagnoses drop after 2003 suicide warning
Propylthiouracil associated with increased risk of serious liver injury
Drug Pipeline/Clinical Updates
Dutasteride reduces prostate cancer incidence in men at high risk
Trial of sunitinib plus paclitaxel for advanced breast cancer discontinued
Paclitaxel stent is treatment option for patients over 70
Drug targets multidrug-resistant tuberculosis
New breast cancer gene targeted for therapeutics
Nebivolol effect similar across ejection fractions
Regulatory/Legislative
IOM recommends more regulation on pharma-doctor relationships
Medicare offers cash incentives for HIT implementation
Medicare Part D plans shift costs for biologic DMARDs
E-prescribing on the rise, but still low overall
FDA gains resources for strengthening product safety

You are subscribed to %%list.name%% as %%emailaddr%%. To unsubscribe from this list click here.To ensure delivery to your Inbox, please add %%email.list%% to your address book. If you need help doing this, click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 1-866-529-2922 at any time, or fax us at 1-218-740-6417. Outside the U.S., please phone 1-218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.